{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:04:25Z","timestamp":1791921865638,"version":"4.3.4"},"reference-count":37,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncology Practice"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec><jats:title>PURPOSE:<\/jats:title><jats:p> Patients who carry reduced-activity DPYD polymorphisms have increased fluoropyrimidine (FP) toxicity risk. Although pretreatment DPYD testing is recommended throughout most of Europe, it is not recommended in the United States, and adoption has been limited. The objective of this survey was to describe the current practice in the United States regarding pretreatment DPYD testing and understand the factors deterring oncologists from ordering testing. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p> Survey invitations were e-mailed to 325 medical oncologists practicing in the United States who are members of the SWOG Cancer Research Network Gastrointestinal Cancer, Breast Cancer, or Early Therapeutics Committees. Descriptive statistics were used to evaluate survey responses. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p> Responses were collected from 59 (18.2%) US medical oncologists, of whom 98% strongly or somewhat agree that patients with dihydropyrimidine dehydrogenase (DPD) deficiency have increased toxicity risk and 96% would modify FP dosing for a patient with known DPD deficiency. However, only 32% strongly or somewhat agree that pretreatment DPYD testing is useful to inform FP treatment, 20% have ever ordered pretreatment testing, and 3% order testing for at least 10% of their FP-treated patients. The most important factors that deter oncologists from ordering testing were low prevalence of DPD deficiency (54%) and lack of clinical practice guideline recommendations (48%). <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION:<\/jats:title><jats:p> Clinical adoption of pretreatment DPYD testing is extremely limited in the United States. Utilization may be substantially increased by inclusion in the oncology clinical practice guideline recommendations, coverage through health insurance, and potentially education of medical oncologists regarding available treatment modification guidelines. <\/jats:p><\/jats:sec>","DOI":"10.1200\/op.21.00874","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T20:59:27Z","timestamp":1646341167000},"page":"e958-e965","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":33,"title":["Survey of US Medical Oncologists' Practices and Beliefs Regarding <i>DPYD<\/i> Testing Before Fluoropyrimidine Chemotherapy"],"prefix":"10.1200","volume":"18","author":[{"given":"Kyoin","family":"Koo","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3162-5498","authenticated-orcid":false,"given":"Amy L.","family":"Pasternak","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4771-5930","authenticated-orcid":false,"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor, MI"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-1548","authenticated-orcid":false,"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor, MI"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0501-1035","authenticated-orcid":false,"given":"Daniel L.","family":"Hertz","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11050199"},{"key":"b2","volume-title":"Clinical Practice Guidelines in Oncology. Colon Cancer, Version 3.2021","author":"NCCN"},{"key":"b3","volume-title":"Clinical Practice Guidelines in Oncology. Rectal Cancer, Version 2.2021","author":"NCCN"},{"key":"b4","volume-title":"Clinical Practice Guidelines in Oncology. Pancreatic Cancer, Version 2.2021","author":"NCCN"},{"key":"b5","volume-title":"Clinical Practice Guidelines in Oncology. Gastric Cancer, Version 5.2021","author":"NCCN"},{"key":"b6","volume-title":"Clinical Practice Guidelines in Oncology. Head and Neck Cancer, Version 3.2021","author":"NCCN"},{"key":"b7","volume-title":"Clinical Practice Guidelines in Oncology. Ovarian Cancer, Version 3.2021","author":"NCCN"},{"key":"b8","volume-title":"Clinical Practice Guidelines in Oncology. Colon Cancer, Version 8.2021","author":"NCCN"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.008"},{"key":"b10","volume-title":"Medical Genetics Summaries","author":"Dean L","year":"2012"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0747"},{"key":"b12","volume-title":"DPYD[gene]-ClinVar-NCBI"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00286-7"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2020-0154"},{"key":"b15","volume-title":"Xeloda [package insert]","year":"2021"},{"key":"b16","volume-title":"Fluorouracil [package insert]","year":"2016"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju298"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1325"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30686-7"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.911"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.022"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00553"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-019-0540-0"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02708-4"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7527"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13967"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2019.04.013"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01609"},{"key":"b29","volume-title":"Message in Our Mailbox: Letter from NCCN (National Comprehensive Cancer Network)","year":"2021"},{"key":"b30","volume-title":"Screening for Dihydropyrimidine Dehydrogenase (DPD) Deficiency in Fluorouracil Patients: Why Not? Institute for Safe Medication Practices","year":"2021"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32022"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12790"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.2217\/pme.14.1"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.306"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-020-0723-0"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1257"},{"key":"b37","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01117-w"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP.21.00874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T22:02:46Z","timestamp":1654898566000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP.21.00874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1200\/OP.21.00874"],"URL":"https:\/\/doi.org\/10.1200\/op.21.00874","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2021-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}